×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Therapeutic: siRNA Therapy for Parkinson's Disease
therapeutic
1,858 words
KG: siRNA
Contents
siRNA Therapy for Parkinson's Disease
💊
Therapeutic Info
Name
siRNA
Key Genes/Proteins
APOE
,
SETX
Linked Hypotheses
1 hypotheses
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (71)
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar
Score: 0.61
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
LRP1-Dependent Tau Uptake Disruption
Score: 0.60
Extracellular Vesicle Biogenesis Modulation
Score: 0.58
Cryptic Exon Silencing Restoration
Score: 0.53
Microglia-Derived Extracellular Vesicle Engineering for Targ
Score: 0.48
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.47
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration
Score: 0.62
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
← Prev
pg 4/4
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
SETX Gene
gene · KG edge: targets
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: inhibits
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 3 hypotheses
Adipose-Derived Mesenchymal Stem Cell Therapy for Early
clinical · Pages share 3 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 3 hypotheses
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-
clinical · Pages share 3 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 3 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 3 hypotheses
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT
clinical · Pages share 3 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (2 edges)
siRNA
inhibits
APOE
siRNA
targets
SETX
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.